+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Translational Autoimmunity, Volume 2. Treatment of Autoimmune Diseases. Translational Immunology

  • Book

  • January 2022
  • Elsevier Science and Technology
  • ID: 5390295

Translational Autoimmunity: Treatment of Autoimmune Diseases, Volume Two in the Translational Immunology series, focuses on advances in therapeutic modalities in autoimmune diseases. Efficacy and safety of not only the current biologic therapies, but also novel drug targets are discussed. Therapeutic targeting of B regulatory cells, T regulatory cells, as well as the immunomodulation effects of nanoparticles and organisms are also covered, along with our� understanding and future challenges of prognostic significance of treatments in autoimmune diseases.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. Introduction on therapeutic opportunities for autoimmunity 2. Innate lymphoid cells as therapeutic targets in autoimmune diseases 3. B regulatory cells in patients with autoimmune diseases: pathogenic significance, therapeutic potential 4. Regulatory T cells in autoimmunity and potential therapeutic targets 5. Application of IL-6 antagonists in autoimmune disorders 6. The search for monomer interaction-based alternative TNFa therapies 7. Generation of thymic cells from pluripotent stem cells for basic research and cell therapy 8. The NLRP3 inflammasome pathway in autoimmune diseases: a chronotherapeutic perspective? 9. Plasmocytes infiltrating autoimmune organs and their putative targeting 10. Biological aging and autoimmunity 11. Efficacy and safety of biologic treatment in autoimmune diseases 12. Nutritional implications for the pathophysiology and treatment of autoimmune disorders 13. Dysbiosis and probiotic applications in autoimmune diseases 14. Precision medicine in managing chronic conditions with an immunological component 15. New advanced therapy medicinal products in treatment of autoimmune diseases 16. Targeting of autoimmune disorders through metal nanoformulation in overcoming the fences of conventional treatment approaches 17. Immunomodulatory effects of parasites on autoimmunity 18. Prediction of autoimmune diseases: from bench to bedside

Authors

Nima Rezaei Professor, Department of Immunology, School of Medicine; Head, Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences; Founding President, Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA),Universal Scientific Education and Research Network (USERN),Tehran, Iran. Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the founding President of the Universal Scientific Education and Research Network (USERN). Professor Rezaei has already been the Director of more than 55 research projects and has designed and participated in several international collaborative projects. Professor Rezaei is an editorial assistant or board member for more than 30 international journals. He has edited more than 35 international books, has presented more than 500 lectures/posters in congresses/meetings, and has published more than 1,000 scientific papers in the international journals.